NCT07409571 Palatal Wound Healing After Free Gingival Graft Surgery
| NCT ID | NCT07409571 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kahramanmaras Sutcu Imam University |
| Condition | Gingival Recession, Localized |
| Study Type | INTERVENTIONAL |
| Enrollment | 55 participants |
| Start Date | 2025-10-16 |
| Primary Completion | 2026-05-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 55 participants in total. It began in 2025-10-16 with a primary completion date of 2026-05-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled clinical trial aims to evaluate the effects of topical triamcinolone acetonide application on wound healing and patient-reported outcomes at the palatal donor site following free gingival graft (FGG) surgery. A total of 55 patients with mucogingival deficiencies requiring FGG will be randomly assigned to either a control group receiving a collagen membrane or a test group receiving topical triamcinolone acetonide at the donor site. All palatal donor areas will be protected with a periodontal dressing. Clinical assessments will be performed on postoperative days 3, 7, 14, and 30. Wound epithelialization will be evaluated using the hydrogen peroxide bubbling test, while wound healing and scar formation will be assessed using the Landry, Turnbull, and Howley index and the modified Manchester Scar Scale, respectively. Patient-centered outcomes, including postoperative pain, discomfort, analgesic consumption, and oral health-related quality of life, will be assessed using visual analog scales and the Oral Health Impact Profile-14 questionnaire. The findings of this study are expected to provide evidence regarding the potential benefits of topical corticosteroid use in reducing palatal donor site morbidity following FGG surgery.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older * Patients presenting with insufficient attached gingiva and/or gingival recession requiring free gingival graft surgery * Systemically healthy individuals (ASA I) * Full-mouth plaque score (FMPS) \< 15% and full-mouth bleeding score (FMBS) \< 15% at the time of surgery * Ability and willingness to provide written informed consent and comply with study procedures Exclusion Criteria: * Presence of systemic diseases that may affect wound healing (e.g., diabetes mellitus, immunological disorders) * Use of systemic corticosteroids, immunosuppressive drugs, or anti-inflammatory medications within the last 3 months * Current smokers or tobacco users * Pregnancy or lactation * History of periodontal surgery at the palatal donor site * Presence of active infection, ulceration, or pathological lesions at the palatal donor area * Known allergy or hypersensitivity to corticosteroids, collagen materials, or study-related medications
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07409571 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gingival Recession, Localized. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07409571 currently recruiting?
Yes, NCT07409571 is actively recruiting participants. Contact the research team at dtesrabozkurt@gmail.com for enrollment information.
Where is the NCT07409571 trial being conducted?
This trial is being conducted at Kahramanmaraş, Turkey (Türkiye).
Who is sponsoring the NCT07409571 clinical trial?
NCT07409571 is sponsored by Kahramanmaras Sutcu Imam University. The trial plans to enroll 55 participants.